Eylea Sales Continue to Increase; Lucentis Gains New Indications

August 11, 2017: By Joan McKenna

Lucentis and EyleaRegeneron reported that its Q2-2017 net sales of Eylea in the US totaled $919 million, an increase of 11 percent over Q2-2016 net sales of $831 million.

Bayer commercializes Eylea outside the US, and its Q2-2017 net sales of the anti-VEGF increased to $542 million, up 10 percent over $486 million in Q2-2016. Regeneron said it recognized $191 million from its share of Bayer’s Eylea sales, compared with $167 million in Q2-2016.

Roche reported that Lucentis’ Q2-2017 sales in the US totaled about $348 million (CHF $335 million, conversion Aug. 11, 2017), a 5 percent decline from Q2-2016 sales. Still, revenues for the retinal treatment were up 2 percent for the first half of the year at $755 million (CHF $727 million). Roche noted that Lucentis gained US FDA approval for all forms of diabetic retinopathy during the quarter.

Novartis sells Lucentis outside the US, and its Q2-2017 sales totaled $477 million, up 5 percent in constant currency but flat in US dollars. Novartis said Lucentis has gained added labeling for choroidal neovascularization in 51 countries, as well as Europe, where the indication was approved in 2016, and the Lucentis prefilled syringe has launched in 32 countries.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022